email print share on Facebook share on Twitter share on LinkedIn share on reddit pin on Pinterest

EXHIBITORS Nordic countries

Sweden's SF Bio and Finland's Finnkino merger to create number-one cinema chain in Scandinavia

by 

- Swedish private equity company Ratos, which owns Finnkino, acquires 60% of the shares in SF Bio from the Bonnier media concern

Swedish private equity company Ratos, which already controls Finland’s leading cinema chain Finnkino, has acquired 60% of the shares in SF Bio, Sweden’s No 1 exhibitor, from the Bonnier media concern, which keeps its 40% stake.

The merger of the two companies (which also covers Norway’s SF Kino) will create the largest theatrical operator in the Nordic countries and the sixth largest in Europe, with 67 cinemas/440 screens in Sweden, Norway, Finland, Estonia, Latvia and Lithuania, taking an annual 30 million admissions. The Swedish division includes 282 auditoria at 43 venues.

(The article continues below - Commercial information)
Hot docs EFP inside

According to Sweden’s DN, managing director Jan Bernhardsson, of SF Bio, will become chief executive of the new enterprise which will hold on to the names of SF Bio and Finnkino. The take-over will need the approval of the competition authorities in the countries involved, and will most likely be completed by the end of April.

“If SF Bio will maintain its current strong position, it will require substantial investments in technology – that is the reason why we, with Ratos, have decided to generate an even stronger company,” said managing director Jonas Bonnier (photo), of the Bonnier media concern, when he announced the sale.

According to DN, Sweden’s theatres are owned by SF Bio (30%), Folkets Hus & Parker (20%), Svenska Bio (14%), Våra Gårdar (7%), Eurostar (3%), Bygdegårdarna (3%), Others (18%). The market share is controlled by SF Bio (67%), with Svenska Bio second (16%). – Before a sister company of Swedish major, Svensk Filmindustri, SF Bio is valued at $0.47 billion (SEK 3 billion).

(The article continues below - Commercial information)

Did you enjoy reading this article? Please subscribe to our newsletter to receive more stories like this directly in your inbox.

Privacy Policy